Tag Archives: gemini

Senseonics Q4 ’25 Earnings; BI Terminates Ph2 MASH Program

Two cardiometabolic-related news items have been observed: Senseonics hosted its Q4 ’25 earnings call (view press release), and BI discontinued its Ph2 BI 770371 asset in MASH (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Insulet, Senseonics, Skye, and Biocon Q1 ‘25 Earnings; Zealand and Roche Make it Official; Akero Presents MASH Data at EASL 2025; Lilly Initiates New Ph3 Tirzepatide Study in T1DM 

A series of cardiometabolic-related news items has been observed from Insulet, Senseonics, Zealand Pharma, Akero Therapeutics, Lilly, Skye Bioscience, and Biocon. Below, FENIX provides highlights and insights for the respective news items.  

This content is for Read Less members only.
Register
Already a member? Log in here